Cardiovascular Disease Doctors in Franklin, TN Accepting Medicare

4 Cardiovascular Disease doctors found. Showing 1 - 4

Thomas Tyree Whitfield, M.D. Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4323 Carothers Pkwy Ste 308, Franklin, TN 37067 Phone: 615-565-6670    Fax: 615-565-6677

Thomas A Thompson, M.D. Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 4323 Carothers Pkwy, Suite 308, Franklin, TN 37067 Phone: 615-565-6634    Fax: 615-565-6677

Dr. Britten Farrar Young, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4323 Carothers Pkwy Ste 308, Franklin, TN 37067 Phone: 615-565-6670    Fax: 615-565-6677

Jonathan Li, M.D. Internal Medicine - Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 730 Cool Springs Blvd Ste 800, Franklin, TN 37067 Phone: 615-468-4000

News Archive

AspenBio Pharma reports on Premarket Notification submission plans for its ELISA format AppyScore test

AspenBio Pharma, Inc., an emerging bio-science company dedicated to the development of novel diagnostics and drugs for humans and animals, reported on its progress and plans for the Premarket Notification 510(k) submission of its ELISA format AppyScore™ test. AppyScore is the first blood-based test designed to aid in the evaluation of patients suspected of having acute appendicitis.

First Edition: September 3, 2013

Today's headlines include reports about interest in and action surrounding state health exchange call centers.

Adding common epilepsy drug to morphine can result in better pain control, say IU researchers

Adding a common epilepsy drug to a morphine regimen can result in better pain control with fewer side effects. Moreover, the combination can reduce the dosage of the opioid needed to be effective, according to a team of pain researchers at Indiana University.

Roche's P2X3 receptor program for chronic pain licensed to Afferent Pharmaceuticals

Roche announced today it has licensed its P2X3 receptor program aimed at developing first-in-class treatments for chronic pain to Afferent Pharmaceuticals. Afferent was co-founded by Anthony Ford, Ph.D., Pappas Ventures, and Third Rock Ventures, and is focused on developing compounds that treat chronic pain by targeting a novel biological pathway.

Read more Medical News

› Verified 5 days ago